Highlights Marksans Pharma Limited Bombay S.E.

Equities

MARKSANS

INE750C01026

Delayed Bombay S.E. Other stock markets 01:23:07 14/05/2024 pm IST			5-day change	1st Jan Change
158.5 ^INR	+1.64%		+0.44%	-1.46%

18/04	Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA	MT
14/02	Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA	18/04	MT
Marksans Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Marksans Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI
Marksans Pharma Arm Gets UK Regulator's Approval to Market Cyanocobalamin Tablets	06/11	MT
Marksans Pharma Undergoes Successful Inspection from German Health Authorities	01/11	MT
Marksans Pharma Gets US FDA Nod for Esomeprazole Magnesium Delayed-Release Capsules	03/23/03	MT
Marksans Pharma Limited Announces US FDA Approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg	03/23/03	CI
Marksans Pharma Limited Approves Payment of Dividend	28/23/28	CI
Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets	22/23/22	CI
Marksans Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23	08/23/08	CI
Marksans Pharma's Goa Plant Gets Two Observations from US FDA	07/23/07	MT
Marksans Pharma Gets US FDA Nod for Pain Relief Drug	12/23/12	MT
Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg	12/23/12	CI
Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023	30/23/30	CI
Marksans Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30/23/30	CI
Marksans Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/23/30	CI
Marksans Pharma Completes Acquisition of Manufacturing Site in Goa, India	19/23/19	MT
Marksans Pharma Limited acquired Bulk Pharmaceutical Business of Tevapharm India Private Limited.	19/23/19	CI
Marksans Pharma Limited Announces US FDA Approval for Famotidine Tablets USP, 10 Mg and 20 Mg	10/23/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Marksans Pharma Limited Bombay S.E.

Equities

MARKSANS

INE750C01026

Highlights

Filters